NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 4 June 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Michael Chambers Present for items 5.1 to 6.2.2
5. Dawn Cooper Present for items 1.1 to 5.2.2
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Pedro Saramago Goncalves Present for all items
11. John Hampson Present for all items
12. Louise Hunt Present for all items
13. Dr Steven Lloyd Present for items 1.1 to 5.2.2
14. Iain McGowan Present for all items
15. Ugochi Nwulu Present for all items
16. Stella O’Brien Present for all items
17. Dr Clare Offer Present for all items
18. Amit Parekh Present for items 5.1 to 6.2.2
19. Dr Kate Ren Present for all items
20. Professor Andrew Renehan Present for items 1.1 to 5.2.2
21. Dr Arpit Srivastava Present for items 1.1 to 5.2.2
22. Dr Satish Venkateshan Present for items 1.1 to 4.2.2 and 6.1 to 6.2.2

NICE staff (key players) present

Jacoline Bouvy, Programme Director Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 1.1 to 5.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2 and 6.1 to 6.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

George Millington, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Celia Mayers, Project Manager Items 5.1 to 5.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Zain Hussain, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Emily Crowe, Associate Director Items 6.1 to 6.2.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Luke Cowie, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Alex Allen, Peninsula Technology Assessment Group (PenTAG) Items 1.1 to 4.1.3

Madhusubramanian Muthukumar, Peninsula Technology Assessment Group (PenTAG) Items 1.1 to 4.1.3

Rebecca Bresnahan, LRiG Items 5.1 to 5.1.3

James Mahon, LRiG Items 5.1 to 5.1.3

Neelam Kalita, Southampton Health Technology Assessments Centre (SHTAC) Items 6.1 to 6.1.3

Geoff Frampton, Southampton Health Technology Assessments Centre (SHTAC) Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Michela Guglieri, Clinical expert, nominated by Duchenne UK Items 1.1 to 4.1.3

Anne-Marie Childs, Clinical expert, nominated by Duchenne UK Items 1.1 to 4.1.3

Robert Burley, Patient expert, nominated by Muscular Dystrophy UK Items 1.1 to 4.1.3

Fiona Marley, NHSE Commissioning expert Items 1.1 to 4.1.2

Peter Clark, CDF Lead, NHS England Items 5.1 to 5.1.3

Dr Karthik Ramasamy, Associate Professor and Consultant Haematologist – clinical expert, nominated by the UK Myeloma Society Items 5.1 to 5.1.3

Dr Rakesh Popat, Consultant Haematologist – clinical expert, nominated by Johnson & Johnson Innovative Medicine Items 5.1 to 5.1.3

Caroline Donoghue, Senior Policy Officer, Myeloma UK – patient expert, nominated by Myeloma UK Items 5.1 to 5.1.3

Kathryn Oddie, Patient expert, nominated by Myeloma UK Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Richard Nicholas welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Alex Cale and Elizabeth Thurgar.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 07 May 2024.

### Appraisal of Vamorolone for treating Duchenne muscular dystrophy [ID4024]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Santhera Pharmaceuticals.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11135/documents)
		3. The chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, clinical, patient and commissioning experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Vamorolone for treating Duchenne muscular dystrophy [ID4024] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11135)

### Appraisal of teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]

* 1. Part 1 – Open session
		1. The chair, Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Johnson & Johnson Innovative Medicine.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11418/documents)
		3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ugochi Nwulu, Dr Prithwiraj Das and Iain McGowan.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11418)

### Appraisal of Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

* 1. Part 1 – Open session
		1. The chair welcomed the invited external assessment group representatives, members of the public and company representatives from Theramex.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11131/documents)
		3. The chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11131)

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 02 July 2024 and will start promptly at 09:30am.